Literature DB >> 17454633

Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.

Bernd Kasper1, Gerlinde Egerer, Martina Gronkowski, Sabine Haufe, Thomas Lehnert, Michael Eisenhut, Gunhild Mechtersheimer, Anthony D Ho, Uwe Haberkorn.   

Abstract

Positron emission tomography (PET) using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) is used as a functional imaging technique for the staging and follow-up of lymphomas. However, additional information about the tumor proliferation rate using 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) may be useful for the assessment of prognosis. We enrolled 48 patients with Hodgkin's (n = 15) and non-Hodgkin's lymphoma (n = 33) with residual masses >2 cm examined by tracer studies with FDG and FLT. The results were related to median overall and progression-free survival. In 15 out of 48 patients analysed using FDG, positive results were found. Using FLT, 10 out of 48 patients were positive. 33 patients were FDG negative. Eight patients were positive both using FDG and FLT. Overall survival for patients with a negative PET scan was significantly higher than for patients with positive PET, irrespective of the tracer used. FLT alone was able to discriminate between patients with long or short overall survival. However, there was no statistical significance comparing FDG/FLT negative versus FDG negative alone. Although FDG detected more lesions than did FLT, the additional biological characterization of tumor tissue with respect to proliferation by FLT might be useful by providing complementary information for the identification of recurrence. However, the present data show no advantage of combined FDG/FLT studies over FDG alone with respect to the prediction of survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454633     DOI: 10.1080/10428190601113568

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Molecular imaging with FLT: a case of Cassandra's curse?

Authors:  Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08       Impact factor: 9.236

2.  A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.

Authors:  Esther Mena; Maria Liza Lindenberg; Baris I Turkbey; Joanna Shih; Jean Logan; Stephen Adler; Karen Wong; Wyndham Wilson; Peter L Choyke; Karen A Kurdziel
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

3.  Impact of the definition of peak standardized uptake value on quantification of treatment response.

Authors:  Matt Vanderhoek; Scott B Perlman; Robert Jeraj
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

4.  Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.

Authors:  Lucia Zanoni; Alessandro Broccoli; Alessandro Lambertini; Cinzia Pellegrini; Vittorio Stefoni; Filippo Lodi; Cristina Fonti; Cristina Nanni; Pier Luigi Zinzani; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-17       Impact factor: 9.236

Review 5.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

Review 6.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

7.  Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Authors:  Nicolas Graf; Ken Herrmann; Jürgen den Hollander; Falko Fend; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Meyer zum Büschenfelde; Christian Peschel; Markus Schwaiger; Tobias Dechow; Andreas K Buck
Journal:  Mol Imaging Biol       Date:  2008-08-14       Impact factor: 3.488

8.  Impact of different standardized uptake value measures on PET-based quantification of treatment response.

Authors:  Matt Vanderhoek; Scott B Perlman; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-06-17       Impact factor: 10.057

9.  Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

Authors:  Adrianus J de Langen; Bianca Klabbers; Mark Lubberink; Ronald Boellaard; Marieke D Spreeuwenberg; Ben J Slotman; Remco de Bree; Egbert F Smit; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

Review 10.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.